Core Insights - MannKind Corporation will showcase its inhaled insulin product, Afrezza, at the American Diabetes Association's 85th Scientific Sessions from June 20-23, 2025, in Chicago [1][5] - Dr. Michael J. Haller will present results from the INHALE-1 clinical trial, focusing on inhaled insulin treatment for children and adolescents aged 4-17 [2][3] - MannKind plans to submit a Supplemental Biologics License Application for a pediatric indication for Afrezza in mid-2025, following the release of topline results from the full pediatric data set in Q2 2025 [5] Company Overview - MannKind Corporation specializes in developing and commercializing inhaled therapeutic products and delivery devices for endocrine and orphan lung diseases [6][7] - The company aims to address serious unmet medical needs through innovative dry-powder formulations and inhalation devices, providing rapid and convenient delivery of medications [7] Upcoming Events - The ADA's Scientific Sessions will feature a symposium titled "Future Ready," where breakthrough advancements in pediatric Type 1 diabetes care will be discussed [3] - MannKind will host a booth (1617) at the event for scientific exchange and to showcase its products [4]